Novel Peptide Restores Muscle Mitochondrial Function in Metabolic Disease Model

Skeletal muscle mitochondrial dysfunction is a hallmark of various metabolic diseases such as Type 2 Diabetes, obesity, and sarcopenia. This dysfunction contributes significantly to insulin resistance, reduced energy expenditure, and progressive muscle weakness. While current treatments manage symptoms, they often fail to directly address the underlying mitochondrial defects. There is a critical need for therapeutic strategies that can effectively restore mitochondrial health and function in skeletal muscle.

Treatment with MitoPeptide-X significantly improved key indicators of mitochondrial function and muscle performance in the obese mice. The higher dose, 1.0 mg/kg, demonstrated the most pronounced effects. Mitochondrial respiration, measured by oxygen consumption rates, was markedly enhanced. > The 1.0 mg/kg dose of MitoPeptide-X increased maximal mitochondrial respiration by 45% (p<0.001) and ATP production by 38% (p<0.005) in skeletal muscle compared to vehicle-treated controls. Furthermore, muscle strength, assessed via grip strength tests, improved by 22% (p<0.01) in the high-dose group. These improvements were correlated with a 2.3-fold increase (p<0.001) in the expression of PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha), a master regulator of mitochondrial biogenesis and function.